AU2003219959B2 - Novel compositions and methods for cancer - Google Patents

Novel compositions and methods for cancer Download PDF

Info

Publication number
AU2003219959B2
AU2003219959B2 AU2003219959A AU2003219959A AU2003219959B2 AU 2003219959 B2 AU2003219959 B2 AU 2003219959B2 AU 2003219959 A AU2003219959 A AU 2003219959A AU 2003219959 A AU2003219959 A AU 2003219959A AU 2003219959 B2 AU2003219959 B2 AU 2003219959B2
Authority
AU
Australia
Prior art keywords
seq
protein
expression
gene
candidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003219959A
Other languages
English (en)
Other versions
AU2003219959A1 (en
Inventor
David W. Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sagres Discovery Inc
Original Assignee
Sagres Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagres Discovery Inc filed Critical Sagres Discovery Inc
Publication of AU2003219959A1 publication Critical patent/AU2003219959A1/en
Application granted granted Critical
Publication of AU2003219959B2 publication Critical patent/AU2003219959B2/en
Priority to AU2008229749A priority Critical patent/AU2008229749A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003219959A 2002-03-01 2003-02-28 Novel compositions and methods for cancer Ceased AU2003219959B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008229749A AU2008229749A1 (en) 2002-03-01 2008-10-01 Novel compositions and methods for cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/087,192 2002-03-01
US10/087,192 US7892730B2 (en) 2000-12-22 2002-03-01 Compositions and methods for cancer
PCT/US2003/006235 WO2003073826A2 (en) 2002-03-01 2003-02-28 Novel compositions and methods for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008229749A Division AU2008229749A1 (en) 2002-03-01 2008-10-01 Novel compositions and methods for cancer

Publications (2)

Publication Number Publication Date
AU2003219959A1 AU2003219959A1 (en) 2003-09-16
AU2003219959B2 true AU2003219959B2 (en) 2008-07-31

Family

ID=27787530

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003219959A Ceased AU2003219959B2 (en) 2002-03-01 2003-02-28 Novel compositions and methods for cancer
AU2008229749A Abandoned AU2008229749A1 (en) 2002-03-01 2008-10-01 Novel compositions and methods for cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008229749A Abandoned AU2008229749A1 (en) 2002-03-01 2008-10-01 Novel compositions and methods for cancer

Country Status (6)

Country Link
US (1) US7892730B2 (enExample)
EP (2) EP2014669A3 (enExample)
JP (2) JP2006507794A (enExample)
AU (2) AU2003219959B2 (enExample)
CA (1) CA2477974A1 (enExample)
WO (1) WO2003073826A2 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878552A1 (en) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
EP1078098A1 (en) 1998-05-04 2001-02-28 Dako A/S Method and probes for the detection of chromosome aberrations
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1363938B1 (en) * 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
EP1307483A2 (en) * 2000-08-10 2003-05-07 MERCK PATENT GmbH Iapl-3 a protein inhibitor of apoptosis proteins
US7358040B2 (en) * 2001-08-01 2008-04-15 Rigel Pharmaceuticals, Incorporated MRE 11: modulation of cellular proliferation
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
KR20030056538A (ko) * 2001-12-28 2003-07-04 주식회사 웰진 리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발
GB0206684D0 (en) * 2002-03-21 2002-05-01 Babraham Inst Novel proteins
GB0207224D0 (en) * 2002-03-27 2002-05-08 Novartis Forschungsstiftung Tenascin-W compositions and uses thereof
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US7537905B2 (en) * 2003-01-15 2009-05-26 The Regents Of The University Of California Amplified and overexpressed gene in colorectal cancers
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US7932364B2 (en) 2003-05-09 2011-04-26 Novo Nordisk A/S Compositions and methods for the preparation of human growth hormone glycosylation mutants
US20060205031A1 (en) * 2003-07-07 2006-09-14 1) Universiteit Utrecht Holding B.V. Newly identified cholinephosphotransferases and ethanolaminephosphotransferases
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
WO2005028633A2 (en) * 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of rankl expression
ATE423200T1 (de) * 2003-10-30 2009-03-15 Kazusa Dna Res Inst Foundation Neues plexin-polypeptid, dieses codierende dna und verwendung davon
EP1680437A4 (en) * 2003-11-07 2008-04-09 Genervon Biopharmaceuticals Llc GENETIC SEQUENCES OF MOTONURONOTROPHIC FACTOR
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005058939A2 (en) * 2003-12-16 2005-06-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for inhibition of bcl6 repression
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
EP2495324B1 (en) 2004-04-09 2015-03-04 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
EP1765992A4 (en) * 2004-06-03 2009-01-07 Neose Technologies Inc Truncated galnact2 polypeptides and nucleic acids
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
EP1910570B1 (en) * 2005-07-29 2011-04-13 Oncotherapy Science, Inc. Gene and polypeptide relating to breast cancer
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
GB0521404D0 (en) * 2005-10-20 2005-11-30 Ares Trading Sa Kunitz domain containing protein
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
JP5122474B2 (ja) 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
EP1978999A4 (en) * 2005-12-20 2009-08-19 Univ Central Florida Res Found ISOLATED MCPIP AND APPLICATION METHOD
JP4520951B2 (ja) * 2006-02-07 2010-08-11 リッチランド・バイオ・メディカル株式会社 インスリン分泌誘導剤及びインスリン分泌誘導組成物
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2044215B1 (en) * 2006-07-21 2015-03-25 Epigenomics AG Methods for analyses of cellular proliferative disorders of the prostate
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US8273539B2 (en) 2006-09-25 2012-09-25 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
AU2007324128B2 (en) * 2006-10-10 2013-10-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US20080090229A1 (en) * 2006-10-12 2008-04-17 Engelhard Eric K Devices for generating detectable polymers
US20080124710A1 (en) * 2006-10-12 2008-05-29 Engelhard Eric K Devices for generating detectable polymers
US20100105025A1 (en) * 2006-10-12 2010-04-29 Engelhard Eric K Devices for generating detectable polymers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
WO2008103431A2 (en) * 2007-02-23 2008-08-28 Pronai Therapeutics, Inc. Dnai - liposomes
US9085638B2 (en) * 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US9303291B2 (en) * 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
AU2008354371B2 (en) * 2008-04-10 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2010009350A2 (en) * 2008-07-16 2010-01-21 Burnham Institute For Medical Research Compositions and methods for modulating nod-like receptor activity and uses thereof
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US8778329B2 (en) * 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US9938582B2 (en) * 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CN113373174B (zh) * 2009-12-17 2024-06-11 先锋国际良种公司 玉米事件dp-004114-3及其检测方法
EP2580322B1 (en) 2010-06-09 2018-01-10 Dana-Farber Cancer Institute, Inc. A mek 1 mutation conferring resistance to raf and mek inhibitors
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
KR20130016009A (ko) * 2011-08-03 2013-02-14 주식회사 엘지생활건강 피부 타입별 유전자 다형성 마커 및 이의 용도
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US12703871B2 (en) 2012-04-24 2026-08-11 Pioneer Hi-Bred International, Inc. Maize event DP-004114-3 and methods for detection thereof
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US20180261333A1 (en) * 2017-03-07 2018-09-13 Anivive Lifesciences, Inc. Drug discovery platform
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018195522A1 (en) * 2017-04-21 2018-10-25 Wake Forest University Health Sciences Arid5b overexpression in inflammatory diseases
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
WO2019235581A1 (ja) * 2018-06-06 2019-12-12 国立大学法人大阪大学 Ｒｅｇｎａｓｅ－１が関与する疾患の治療および／または予防方法
CN109593848B (zh) * 2018-11-08 2020-07-10 浙江大学 一种肿瘤相关序列、长链非编码rna及其应用
JP7522424B2 (ja) * 2019-11-15 2024-07-25 公立大学法人大阪 胆道癌又は膵癌治療剤
EP4061426A1 (en) * 2019-11-21 2022-09-28 Friedrich Miescher Institute for Biomedical Research Promoter for the specific expression of genes in agmat-positive cells in layer 2/3 of mouse cortex
US20210292820A1 (en) * 2020-03-20 2021-09-23 Applied Dna Sciences, Inc. Compositions and methods for detecting and treating sars-cov-2
US20230340524A1 (en) * 2020-07-08 2023-10-26 The Jackson Laboratory Transgenic mouse models supporting human innate immune function
DE102020125457A1 (de) * 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
CA3222729A1 (en) * 2021-06-18 2022-12-22 Rui Liu Substance and method for tumor assessment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360733A (en) * 1992-10-01 1994-11-01 La Jolla Cancer Research Foundation Human β1-6 n-acetylglucosaminyl transferase
WO1995028490A1 (en) * 1994-04-15 1995-10-26 Alliance Pharmaceutical Corp. Expression vector with non-viral promoter
WO2001057182A2 (en) * 2000-01-31 2001-08-09 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990010448A2 (en) 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5759776A (en) 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
EP0877752B1 (en) 1996-01-23 2003-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6074825A (en) 1997-07-31 2000-06-13 Maine Medical Center Stable encapsulated reference nucleic acid and method of making
US6153441A (en) 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001264559A1 (en) 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002022660A2 (en) 2000-09-11 2002-03-21 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2003281515A1 (en) * 2002-07-19 2004-02-09 Cellzome Ag Protein complexes of cellular networks underlying the development of cancer and other diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360733A (en) * 1992-10-01 1994-11-01 La Jolla Cancer Research Foundation Human β1-6 n-acetylglucosaminyl transferase
WO1995028490A1 (en) * 1994-04-15 1995-10-26 Alliance Pharmaceutical Corp. Expression vector with non-viral promoter
WO2001057182A2 (en) * 2000-01-31 2001-08-09 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Kudo, S. and Fukuda, M. (1991) The Journal of Biological Chemistry 266: 8483-8489 *
Lai, R. et al (1999) American Journal of Clinical Pathology 111: 488-494 *
Santamaria, M. et al (1996) Cancer Research 56: 3526-3529 *
Sikut, R. et al (1997) Biochemical and Biophysical Research Communications 238: 612-616 *
Sikut, R. et al (1999) International Journal of Cancer 82: 52-58 *
Traweek, S. T. et al (1993) The American Journal of Surgical Pathology 17(10): 1011-1019 *
Treasure, J. et al (1992) Journal of Clinical Pathology 45: 1018-1022 *

Also Published As

Publication number Publication date
AU2003219959A1 (en) 2003-09-16
EP2014669A2 (en) 2009-01-14
WO2003073826A2 (en) 2003-09-12
AU2008229749A1 (en) 2008-10-30
EP2014669A3 (en) 2009-02-25
US20020182586A1 (en) 2002-12-05
CA2477974A1 (en) 2003-09-12
EP1558623A2 (en) 2005-08-03
US7892730B2 (en) 2011-02-22
EP1558623A4 (en) 2006-04-05
JP2006507794A (ja) 2006-03-09
JP2010124828A (ja) 2010-06-10
WO2003073826A8 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
US7892730B2 (en) Compositions and methods for cancer
US20040072154A1 (en) Novel compositions and methods for cancer
US20030216558A1 (en) Novel compositions and methods for cancer
US20100216713A1 (en) Novel compositions and methods in cancer associated with altered expression of prlr
US20030194702A1 (en) Novel compositions and methods for cancer
US20040072264A1 (en) Novel compositions and methods for cancer
US20030232334A1 (en) Novel compositions and methods for cancer
AU2003225826B2 (en) Novel compositions and methods in cancer associated with altered expression of MCM3AP
US20030099963A1 (en) Novel compositions and methods in cancer associated with altered expression of TBX21
US7700274B2 (en) Compositions and methods in cancer associated with altered expression of KCNJ9
AU2003230669B2 (en) Novel compositions and methods in cancer associated with altered expression of TBX21
US20030087252A1 (en) Novel compositions and methods in cancer associated with altered expression of PRDM11
AU2008207455A1 (en) Novel compositions and methods in cancer associated with altered expression of TBX21

Legal Events

Date Code Title Description
MK24 Application lapsed reg. 22.2e(2) - failure to pay response fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE EXAM RESPONSE FEE HAS BEEN EXTENDED TO 16 JUL 2008.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired